NCT03529123 - Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) | Biotech Hunter

Enrollment

247

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

November 25, 2019

Study Completion Date

November 25, 2019

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)

"Pharmaceutical form: Injection~Route of administration: Subcutaneous"

DRUG

INSULIN GLARGINE (HOE901)

"Pharmaceutical form: Injection~Route of administration: Subcutaneous"

DRUG

Metformin

"Pharmaceutical form: Tablet~Route of administration: Oral"

DRUG

Insulin Glulisine (HMR1964)

"Pharmaceutical form: Injection~Route of administration: Subcutaneous"

Trial Locations (13)

110029

Investigational Site Number 010, New Delhi

411040

Investigational Site Number 016, Pune

422002

Investigational Site Number 05, Nashik

500063

Investigational Site Number 06, Hyderabad

500072

Investigational Site Number 07, Hyderabad

560092

Investigational Site Number 01, Bangalore

590010

Investigational Site Number 012, Belagavi

600086

Investigational Site Number 013, Chennai

625020

Investigational Site Number 014, Madurai

641009

Investigational Site Number 017, Coimbatore

700107

Investigational Site Number 04, Kolkata

Unknown

Investigational Site Number 08, Jaipur

Investigational Site Number 018, Lucknow